

CITATION REPORT

List of articles citing

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study

DOI: 10.1016/j.clinthera.2007.07.018

Clinical Therapeutics, 2007, 29, 1354-67.

Source: <https://exaly.com/paper-pdf/42034338/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
350	Novel markers of inflammation in atherosclerosis. 2008 , 10, 164-70		35
349	Lipid management: considerations in acute coronary syndrome. 2008 , 10, 334-41		
348	Managing the patient with hypertriglyceridemia: a practical approach for nurse practitioners. 2008 , 20 Suppl 2, 1-14; quiz 15		1
347	Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. 2008 , 101, 1003-8		82
346	Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. 2008 , 102, 429-33		73
345	Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. 2008 , 102, 1040-5		47
344	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. 2008 , 102, 1K-34K		280
343	Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. 2008 , 2, 79-90		34
342	Are All Fish Equally Close to the Heart?Reply. 2008 , 83, 724-725		
341	Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. 2008 , 6, 391-409		171
340	Omega-3 fatty acids for cardioprotection. 2008 , 83, 324-32		194
339	Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. 2008 , 9, 2947-53		15
338	Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. 2008 , 27, 659-66		34
337	Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. 2008 , 9, 2939-45		16
336	Effect of fish oil on arrhythmias and mortality: systematic review. 2008 , 337, a2931		160
335	Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. 2008 , 9, 1237-48		63
334	Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. 2008 , 28, 958-73		96

333	Moderate-to-Severe Psoriasis. 2008,	
332	Dispelling the myths about omega-3 fatty acids. 2008, 120, 92-100	2
331	Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. 2008, 6, 1303-10	3
330	An updated review of acitretin--a systemic retinoid for the treatment of psoriasis. 2008, 4, 953-64	26
329	Are All Fish Equally Close to the Heart?Reply. 2008, 83, 724-725	
328	Fish oil in the treatment of dyslipidemia. 2008, 15, 167-74	26
327	Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. 2008, 15, 142-6	15
326	Bibliography. Current world literature. Diabetes and the endocrine pancreas. 2008, 15, 193-207	
325	Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. 2008, 87, 1981S-90S	108
324	Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. 2009, 5, 793-9	27
323	Advances in lipid testing and management in patients with diabetes mellitus. 2009, 15, 641-52	3
322	Omega-3 Fatty Acids. 2009, 326-338	7
321	Combination Therapy for Dyslipidemia. 2009, 352-362	1
320	Nutrition and heart failure: impact of drug therapies and management strategies. 2009, 24, 60-75	30
319	Fatty acids and obesity. 2009, 15, 4117-25	10
318	Beneficial Effects of Fish Oil on Human Brain. 2009,	42
317	Review of effect of prescription omega-3 fatty acids on body weight. Commentary. 2009, 121, 200-2	
316	Omega-3 fatty acids for the treatment of elevated triglycerides. 2009, 4, 425-437	16

315	Dyslipidemia and cardiovascular risk: the importance of early prevention. 2009 , 102, 657-67	61
314	Fish Oil and Importance of Its Ingredients in Human Diet. 2009 , 1-45	2
313	The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. 2009 , 121, 145-50	36
312	Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?. 2009 , 60, 93-8	1
311	Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. 2010 , 13, 130-4	3
310	The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. 2009 , 11, 520-7	17
309	Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia. 2009 , 20, 927-39	64
308	The hypolipidemic effect of an ethyl ester of algal-docosahexaenoic acid in rats fed a high-fructose diet. 2009 , 44, 817-26	27
307	Lipid management: considerations in acute coronary syndrome. 2009 , 11, 149-56	0
306	Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. 2009 , 26, 675-90	28
305	Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report. 2009 , 8, 1	36
304	Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. 2009 , 145, 84-6	16
303	Soy constituents: modes of action in low-density lipoprotein management. 2009 , 67, 222-34	21
302	Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. 2009 , 158, 413-28	104
301	Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. 2009 , 29, 609-15	144
300	Omega-3 polyunsaturated fatty acids and cardiovascular diseases. 2009 , 54, 585-94	441
299	Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. 2009 , 3, 33-8	17
298	Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration. 2009 , 3, 275-80	3

297	Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. 2009 , 3, 332-40	60
296	Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. 2009 , 3, 341-4	2
295	Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. 2009 , 69, 1077-105	32
294	Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management. 2009 , 3, 257-273	17
293	Lipid management in the geriatric patient. 2009 , 38, 185-206	3
292	Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study. 2009 , 41, 760-6	33
291	Management of non-high-density lipoprotein abnormalities. 2009 , 207, 328-35	19
290	A review of lipid management in primary and secondary prevention. 2009 , 29, 2-12	41
289	Does Early Nutrition Support Improve ICU Outcomes?. 2009 , 35, 6-8	
288	News bites. 2009 , 35, 12	
287	Triglycerides and coronary heart disease: have recent insights yielded conclusive answers?. 2009 , 20, 275-81	14
286	Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. 2009 , 54, 196-203	19
285	A Long-Lasting Diabetes Prevention Benefit. 2009 , 35, 5	
284	The Low-Down on Lovaza Pricing. 2009 , 35, 3	
283	Clinical Nutrition INSIGHT CME QUIZ. 2009 , 35, 10-11	
282	Fish Oil Therapy. 2009 , 35, 1-4	
281	Glycemic Index and Diabetes. 2009 , 35, 4-6	
280	If Obesity Is Contagious, Acne May Be, Too. 2009 , 35, 8-9	

279	Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. 2009 , 151, 622-30		54
278	Herz-Kreislauf-Erkrankungen: Omega-3-Fettsäuren und Coenzym Q10. 2009 , 21, 275-278		
277	Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome. 2009 , 15, 3446-62		5
276	Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. 2010 , 103, 1260-77		33
275	Effect of fish oil on arrhythmias and mortality: systematic review. 2010 , 2010, 284-287		
274	Traitements des dyslipidémies: moyens pharmacologiques. Indications et recommandations thérapeutiques. 2010 , 7, 1-11		
273	Effect of fish oil on arrhythmias and mortality: systematic review. 2010 , 2010, 369-371		
272	Fish oil for the treatment of cardiovascular disease. 2010 , 18, 258-63		88
271	Potential Approach of Microbial Conversion to Develop New Antifungal Products of Omega-3 Fatty Acids. 2010 , 459-472		1
270	Targeting residual risk: the rationale for the use of non-HDL cholesterol. <i>Southern Medical Journal</i> , 2010 , 103, 434-7; quiz 438-9	0.6	6
269	Production and characterization of linolenic acid enriched structured lipids from lipase-catalyzed interesterification. 2010 , 19, 57-62		9
268	Omega-3 Fatty acids for cardiovascular disease prevention. 2010 , 12, 365-80		37
267	Fish oil for primary and secondary prevention of coronary heart disease. 2010 , 12, 66-72		56
266	The effect of fat intake and antihypertensive drug therapy on serum lipid profile: a cross-sectional survey of serum lipids in male and female hypertensives. 2010 , 343, 37-47		5
265	Management of dyslipidemia in people with type 2 diabetes mellitus. 2010 , 11, 41-51		22
264	Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. 2010 , 105, 1409-12		22
263	Reporting of dietary control frameworks in studies on simvastatin efficacy. 2010 , 29, 352-7		3
262	Combined therapy in the treatment of dyslipidemia. 2010 , 24, 19-28		70

261	Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. 2010 , 3, 79-96	6
260	Exploring newer cardioprotective strategies: EB fatty acids in perspective. 2010 , 104, 664-80	24
259	No accord for the ACCORD-Lipid trial results. 2010 , 1, 47-9	
258	Beyond statin therapy: a review of the management of residual risk in diabetes mellitus. 2010 , 103, 357-62	8
257	Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. 2010 , 26, 907-15	20
256	High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. 2010 ,	5
255	Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. 2010 , 85, 122-8	47
254	Functional food ingredients as adjunctive therapies to pharmacotherapy for treating disorders of metabolic syndrome. 2010 , 42, 317-33	16
253	[Residual vascular risk: recommendations of the Spanish Initiative for the Reduction of Residual Risk]. 2010 , 135, 165-71	5
252	What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?. 2010 , 28, 106-23	9
251	Advancing therapy for hypercholesterolemia. 2010 , 11, 1659-72	22
250	Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. 2010 , 5, 325-328	1
249	The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective. 2010 , 19, 809-14	10
248	Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. 2011 , 5, 483-92	67
247	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. 2011 , 8, 253-65	75
246	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,	
245	Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. 2011 , 118, 187-94	22
244	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. 2011 ,	6

243	Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. 2011 , 23, 230-239	
242	The impact of dietary changes and dietary supplements on lipid profile. 2011 , 27, 488-505	45
241	Greasing the wheels of managing overweight and obesity with omega-3 fatty acids. 2011 , 77, 1114-20	23
240	Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. 2011 , 32, 543-50	194
239	Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β -cell response in subjects with primary hypertriglyceridemia. 2011 , 85, 143-8	17
238	Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial. 2011 , 85, 381-6	36
237	[ESC/EAS Guidelines for the management of dyslipidaemias]. 2011 , 64, 1168.e1-1168.e60	37
236	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 32, 1769-818	2020
235	Using omega-3 fatty acids in the practice of clinical lipidology. 2011 , 5, 424-33	4
234	Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. 2011 , 13, 474-83	211
233	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217 Suppl 1, S1-44	152
232	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217, 3-46	459
231	Dyslipidemia associated with chronic kidney disease. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 41-80.7	78
230	Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters. 2011 , 3, 87-97	15
229	Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. 2011 , 57, 489-94	28
228	Trig-onometry [®] non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. 2011 , 65, 82-101	14
227	Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability. 2011 , 65, 110-6	19
226	Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blIND, 12-week study with an open-label Extension [MARINE] trial). 2011 , 108, 682-90	254

225	High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. 2011 , 46, 521-8	20
224	[Multimodal therapy of dyslipidemia]. 2011 , 6, 10-6	
223	What combination therapy with a statin, if any, would you recommend?. 2011 , 13, 12-22	15
222	Safety review of combination drugs for hyperlipidemia. 2011 , 10, 363-71	14
221	Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. 2011 , 93, 243-52	215
220	Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis. 2011 , 12, 268-74	22
219	Membrane raft organization is more sensitive to disruption by (n-3) PUFA than nonraft organization in EL4 and B cells. 2011 , 141, 1041-8	44
218	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. 2011 , 12, 13-30	50
217	Racial and geographic differences in fish consumption: the REGARDS study. 2011 , 76, 154-8	23
216	Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr ^{-/-} mice. 2012 , 142, 1495-503	35
215	Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. 2012 , 3, 35-46	12
214	Omega-3 fatty acid supplementation and cardiovascular disease. 2012 , 53, 2525-45	139
213	Effect of altering dietary n-6:n-3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study. 2012 , 108, 1280-5	19
212	Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. 2012 , 124, 7-20	7
211	Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. 2012 , 53, 1662-9	82
210	A new pure β eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. 2012 , 10, 687-95	8
209	Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. 2012 , 53, 2429-35	26
208	Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. 2012 , 6, 5-18	194

207	Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. 2012 , 6, 413-26	68
206	American Association of Clinical EndocrinologistsPGuidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. 2012 , 18 Suppl 1, 1-78	312
205	High dose of an n-3 polyunsaturated fatty acid diet lowers activity of C57BL/6 mice. 2012 , 86, 137-40	16
204	Associations between omega-3 poly-unsaturated fatty acids from fish consumption and severity of depressive symptoms: an analysis of the 2005-2008 National Health and Nutrition Examination Survey. 2012 , 86, 155-60	33
203	Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. 2012 , 51, 232-7	111
202	Relative efficacy of antilipemic agents in nonHigh-density lipoprotein cholesterol reduction. 2012 , 25, 447-56	1
201	n-3 Polyunsaturated fatty acids exert immunomodulatory effects on lymphocytes by targeting plasma membrane molecular organization. 2012 , 33, 46-54	52
200	Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. 2012 , 1, 26	9
199	Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement. 2012 , 64, 503-7	2
198	Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). 2012 , 110, 984-92	243
197	Tratamiento de las hiperlipidemias. 2012 , 11, 1145-1152	
196	Lipid lowering drugs and the risk of recurrent venous thromboembolism. 2012 , 130, 859-63	29
195	Lipids as New Targets. 2012 , 279-308	
194	Omega-3 index and smoking in patients with acute ST-elevation myocardial infarction taking statins: a case-control study in Korea. 2012 , 11, 43	9
193	Docosahexaenoic acid-induced unfolded protein response, cell cycle arrest, and apoptosis in vascular smooth muscle cells are triggered by Ca ²⁺ -dependent induction of oxidative stress. 2012 , 52, 1786-95	30
192	The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. <i>Clinical Therapeutics</i> , 2012 , 34, 67-76	3.5 23
191	Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. 2012 , 23, 101-5	91
190	Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. 2013 , 69, 633-51	274

189	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. 2013 , 14, 237-42		21
188	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. 2013 , 170, S16-20		26
187	Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. 2013 , 230, 381-9		52
186	Icosapent ethyl for treatment of elevated triglyceride levels. 2013 , 47, 1517-23		9
185	A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). <i>Clinical Therapeutics</i> , 2013 , 35, 1400-11.e1-3	3.5	81
184	Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. 2013 , 12, 100		51
183	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. 2013 , 8, 329-344		2
182	Demystifying the management of hypertriglyceridaemia. 2013 , 10, 648-61		75
181	Omega-3 fatty acids as a putative treatment for traumatic brain injury. 2013 , 30, 897-906		71
180	Impact of omega-3 fatty acids and/or plant sterol supplementation on non-HDL cholesterol levels of dyslipidemic Indian adults. 2013 , 5, 36-43		24
179	Recomendações da ESC/EAS para a abordagem clínica das dislipidemias. 2013 , 32, 81.e1-81.e50		
178	ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol. 2013 , 111, 454-5		4
177	[Combined treatment: regimens, indications and safety profile]. 2013 , 25, 140-5		1
176	Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. 2013 , 7, 615-25		20
175	What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. 2013 , 15, 104-17		5
174	Beyond statins: lipid management to reduce cardiovascular risk. 2013 , 33, 754-64		13
173	A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. 2013 , 73, 1025-54		18
172	Potential adverse effects of omega-3 Fatty acids in dogs and cats. 2013 , 27, 217-26		44

171 AuthorsPreply. **2013**, 111, 455-6

170 Omega-3 Fatty Acids in Prevention of Cardiovascular Disease in Humans: Chemistry, Dyslipidemia. **2013**, 465-489 1

169 Omega-3 Fatty Acids in Prevention of Cardiovascular Disease in Humans. **2013**, 1-28

168 A fish a day, keeps the cardiologist away! - A review of the effect of omega-3 fatty acids in the cardiovascular system. **2013**, 17, 422-9 10

167 Nutritional properties of dietary omega-3-enriched phospholipids. **2013**, 2013, 965417 39

166 Omega-3 fatty acids and cardiovascular disease: new developments and applications. **2013**, 125, 100-13 63

165 N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics. **2013**, 7, 73-77A 5

164 Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study. **2013**, 8, e62772 17

163 Limited impact of 2 g/day omega-3 fatty acid ethyl esters (Omacor®) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy. **2013**, 11, 3569-81 14

162 The Role of Diet in the Prevention and Treatment of Cardiovascular Disease. **2013**, 541-567 1

161 Asthma in the 21st Century [Unexpected Applications of Ancient Treatments. **2013**,

160 Marine-derived omega-3 fatty acids: fishing for clues for cancer prevention. **2013**, 97-101 4

159 Effect of omega-3 fatty acid ethyl esters on the oxylipin composition of lipoproteins in hypertriglyceridemic, statin-treated subjects. **2014**, 9, e111471 24

158 Icosapent ethyl for the treatment of severe hypertriglyceridemia. **2014**, 10, 485-92 7

157 Combinaton or Individual Lipid-Lowering Therapy-What Is The Right Direction?. **2014**, 02,

156 Role of Omega-3 Polyunsaturated fatty acids in Inflammation and rheumatoid arthritis disorders. **2014**, 2, 3-17

155 Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. **2014**, 9, 149-161 4

154 Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. **2014**, 12, 1045-54 5

153	A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients. 2014 , 126, 268-73	9
152	Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. 2014 , 126, 7-18	50
151	Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects. 2014 , 21, 56-66	4
150	Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study. 2014 , 13, 1	34
149	The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. 2014 , 5, 426-35	61
148	Omega-3 fatty acids: a growing ocean of choices. 2014 , 16, 389	17
147	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. 2014 , 435-453	
146	Dyslipidemias in Kidney Disease. 2014 ,	2
145	Acitretin in psoriasis: an evolving scenario. 2014 , 53, 525-38	36
144	Recent advances in pharmacotherapy for hypertriglyceridemia. 2014 , 56, 47-66	104
143	Clinical Strategies for Managing Dyslipidemias. 2014 , 8, 216-230	1
142	Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders. 2014 , 5, 394-403	43
141	Nutritional treatment for traumatic brain injury. 2014 , 31, 989-99	39
140	Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. 2014 , 8, 94-106	163
139	The effect of nutritional supplements on serum high-density lipoprotein cholesterol and apolipoprotein A-I. 2014 , 14, 253-74	12
138	Does Consumption of Omega-3 Polyunsaturated Fatty Acids Affect Lipid Profile and Fasting Blood Glucose in Patients With Traumatic Spinal Cord Injury? A Double-Blinded Randomized Clinical Trial. 2015 , 30, 333-343	1
137	Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols. 2015 , 99, 41-6	5
136	Nutrition and Coronary Heart Disease Prevention. <i>Contemporary Endocrinology</i> , 2015 , 329-341	0.3

135	Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?. 2015 , 13, 1-21	21
134	The effects of diet-induced obesity on B cell function. 2015 , 179, 90-9	44
133	Lipid Management. 2015 ,	1
132	Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. 2015 , 242, 647-56	45
131	Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3. 2015 , 9, 2129-37	10
130	Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. 2015 , 240, 520-5	15
129	Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. 2015 , 9, 360-7	19
128	Some nutritional supplements may have modest beneficial effects on lipid levels, but the effects of most are negligible. 2015 , 31, 133-136	1
127	Comprehensive Study of the Lipid Classes of Krill Oil by Fractionation and Identification of Triacylglycerols, Diacylglycerols, and Phospholipid Molecular Species by Using UPLC/QToF-MS. 2015 , 8, 2568-2580	38
126	The Role of Omega-3 Fatty Acids in Dyslipidemias. 2015 , 45-64	1
125	Omega-3 fatty acids induce Ca(2+) mobilization responses in human colon epithelial cell lines endogenously expressing FFA4. 2015 , 36, 813-20	18
124	Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. 2015 , 127, 655-63	12
123	Benefits on body fat composition of isocalorically controlled diets including functionally optimized meat products: Role of alpha-linolenic acid. 2015 , 12, 319-331	6
122	Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study. 2016 , 10, 123-8	4
121	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. 2016 , 9, 109-18	10
120	Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. 2016 , 12, 481-490	6
119	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. 2016 , 135, 3-12	9
118	Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia. 2016 , 11, e0154683	28

117	Nutritional management of hyperapoB. 2016 , 29, 202-233	16
116	Acitretin. 2016 , 49-62	
115	Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. 2016 , 118, 138-45	92
114	Positive effects of egg-derived phospholipids in patients with metabolic syndrome. 2016 , 61, 169-74	13
113	Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. 2016 , 16, 229-239	32
112	Significant advancement of mass spectrometry imaging for food chemistry. 2016 , 210, 200-11	49
111	The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. 2016 , 15, 118	91
110	Reducing the burden of obesity-associated cancers with anti-inflammatory long-chain omega-3 polyunsaturated fatty acids. 2016 , 125, 100-7	10
109	Development of an α -linolenic acid containing soft nanocarrier for oral delivery: in vitro and in vivo evaluation. 2016 , 6, 77590-77602	13
108	Importance of propionate for the repression of hepatic lipogenesis and improvement of insulin sensitivity in high-fat diet-induced obesity. 2016 , 60, 2611-2621	82
107	Role of Omega-3 Fatty Acids in Cardiovascular Disorders. 2016 , 513-530	1
106	Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. 2016 , 251, 240-247	7
105	Circulating levels of endocannabinoids and oxylipins altered by dietary lipids in older women are likely associated with previously identified gene targets. 2016 , 1861, 1693-1704	17
104	The future of n-3 polyunsaturated fatty acid therapy. 2016 , 27, 570-578	13
103	Dietary fried fish intake increases risk of CVD: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. 2016 , 19, 3327-3336	27
102	Omega-3 Fatty Acid Supplementation Lowers Serum FSH in Normal Weight But Not Obese Women. 2016 , 101, 324-33	20
101	History and future of omega-3 fatty acids in cardiovascular disease. 2016 , 32, 301-11	22
100	Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. 2016 , 10, 181-91.e1-2	14

99	Linolenic acid increases the G0/G1 switch gene 2 mRNA expression in peripheral blood mononuclear cells from obese patients: a pilot study. 2016 , 15, 36	12
98	Functions of omega-3 fatty acids and FFA4 (GPR120) in macrophages. 2016 , 785, 36-43	61
97	Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. 2017 , 91, 1-9	45
96	Different postprandial metabolic patterns after the consumption of fish oil and lard in healthy Chinese individuals. 2017 , 31, 134-139	
95	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. 2017 , 23, 1-87	535
94	CE: Triglycerides: Do They Matter?. 2017 , 117, 24-31	4
93	Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. 2017 , 28, 327-336	13
92	Weekday variation in triglyceride concentrations in 1.8 million blood samples. 2017 , 58, 1204-1213	11
91	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. 2017 , 34, 300-323	29
90	Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. 2017 , 11, 1152-1160.e2	69
89	Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids. 2017 , 19, 60	26
88	Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same. 2017 , 29, 791-801	4
87	Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?. 2017 , 42 Suppl 12, 3-9	1
86	Is the addition of fish oil to statin therapy in patients with persistent hypertriglyceridemia more effective than statins alone?. 2017 , 20, E12	
85	The Role of Diet in the Prevention and Treatment of Cardiovascular Disease. 2017 , 595-623	3
84	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients. 2017 , 24, 275-289	8
83	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. 2017 , 17, 551	71
82	Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. 2018 , 36, 277-285	3

81	Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. 2018 , 128, 1-10		21
80	Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials. 2018 , 129, 1-12		45
79	Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention. 2018 , 58, 958-971		19
78	Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. 2018 , 31, 67-84		58
77	Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol. 2018 , 18, 83-92		1
76	FFA4 (GPR120) as a fatty acid sensor involved in appetite control, insulin sensitivity and inflammation regulation. 2018 , 64, 92-108		31
75	Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. <i>Clinical Therapeutics</i> , 2018 , 40, 83-94	3-5	13
74	The Impact of Omega 3 Fatty Acids in Atherosclerosis and Arterial Stiffness: An Overview of their Actions. 2018 , 24, 1865-1872		8
73	Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis. 2018 , 97, e13593		10
72	Polyunsaturated Fatty Acids and Their Potential Therapeutic Role in Cardiovascular System Disorders-A Review. 2018 , 10,		116
71	Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. 2018 , 79, 31-37		49
70	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. 2018 , 41, 1281-1288		134
69	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. 2019 , 140, e673-e691		169
68	Diabetes and Atherogenic Dyslipidemia. 2019 , 587-596		1
67	2018 Guidelines for the Management of Dyslipidemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019 , 8, 78-131	3	40
66	2018 Guidelines for the management of dyslipidemia. 2019 , 34, 723-771		79
65	Omega-3 Fatty Acids Effects on Inflammatory Biomarkers and Lipid Profiles among Diabetic and Cardiovascular Disease Patients: A Systematic Review and Meta-Analysis. 2019 , 9, 18867		40
64	Omega-3 fatty acids in coronary heart disease: Recent updates and future perspectives. 2019 , 46, 11-18		16

63	Administration of eicosapentaenoic and docosahexaenoic acids may improve the remodeling and browning in subcutaneous white adipose tissue and thermogenic markers in brown adipose tissue in mice. 2019 , 482, 18-27	14
62	Omega-3 Polyunsaturated Fatty Acids: Benefits and Endpoints in Sport. 2018 , 11,	82
61	Inflammatory Markers and Novel Risk Factors. 2019 , 87-98	
60	Can krill oil be of use for counteracting neuroinflammatory processes induced by high fat diet and aging?. 2020 , 157, 1-14	11
59	Dietary and Pharmacological Fatty Acids and Cardiovascular Health. 2020 , 105,	11
58	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. 2020 , 26, 1196-1224	27
57	Omega-3 PUFA Responders and Non-Responders and the Prevention of Lipid Dysmetabolism and Related Diseases. 2020 , 12,	8
56	Effects of n-3 fatty acids on growth, antioxidant status, and immunity of preweaned dairy calves. 2020 , 103, 2864-2876	4
55	SR-BI as a target of natural products and its significance in cancer. 2020 ,	10
54	Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms. 2020 , 12,	8
53	Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?. 2021 , 219, 107703	31
52	Salmon food matrix influences digestion and bioavailability of long-chain omega-3 polyunsaturated fatty acids. 2021 , 12, 6588-6602	3
51	The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials. 2021 , 57, 102662	2
50	THE STUDY ON HbA1c AND FENOFIBRATE ON THE HDL OF THE PATIENTS SUFFERING FROM DIABETES MELLITUS TYPE-II. 2021 , 77-79	
49	Omega 3 fatty acids effect on the vascular calcification biomarkers fetuin A and osteoprotegerin in hemodialysis patients. <i>Clinical and Experimental Medicine</i> , 2021 , 1	4.9 0
48	Comparison of the Efficacy and Safety of Atorvastatin 40 mg/EB Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study. <i>Clinical Therapeutics</i> , 2021 , 43, 1419-1430	3.5 0
47	Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β -cell function. <i>IScience</i> , 2021 , 24, 102909	6.1 2
46	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021 , 38, 100997	11.3 21

45	Safety Considerations of Pharmacological Treatment. <i>Stroke Revisited</i> , 2021 , 203-219	0.1	0
44	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. 2011 , 230-251		1
43	Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapy. <i>Southern Medical Journal</i> , 2009 , 102, 390-6	0.6	2
42	Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial. <i>Journal of Lipid and Atherosclerosis</i> , 2019 , 8, 221-231	3	1
41	Efficacy of DHA and EPA on Serum Triglyceride Levels of Healthy Participants: Systematic Review. <i>International Journal of Nutrition</i> , 2018 , 3, 22-40	2.2	1
40	Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. <i>Methodist DeBakey Cardiovascular Journal</i> , 2019 , 15, 171-178	2.1	26
39	[Omega-3 polyunsaturated fatty acids in the prevention of atherosclerosis]. <i>Orvosi Hetilap</i> , 2008 , 149, 627-37	0.8	4
38	[The effect of long-chain polyunsaturated ω 3 fatty acids on the arterial stiffness parameters in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy]. <i>Zhurnal Nevrologii I Psikhiiatrii Imeni S S Korsakova</i> , 2015 , 115, 80-84	0.4	2
37	<i>Spinacia oleracea</i> Linn Considered as One of the Most Perfect Foods: A Pharmacological and Phytochemical Review. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019 , 19, 1666-1680	3.2	8
36	Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters. <i>Open Cardiovascular Medicine Journal</i> , 2012 , 6, 122-5	0.7	5
35	Egg Yolk Fatty Acids, Blood Parameters and Some Reproductive Measurements of Japanese Quail Supplemented with Chia Seeds (<i>Salvia hispanica</i> L.). <i>International Journal of Poultry Science</i> , 2019 , 18, 129-135	0.3	4
34	Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Diabetes and Metabolism Journal</i> , 2020 , 44, 78-90	5	3
33	Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?. <i>World Journal of Diabetes</i> , 2015 , 6, 245-58	4.7	20
32	Effects of Statins and ω 3 Fatty Acids on Heart and Brain Tissues: The Clash of the Titans. 2009 , 277-318		
31	Effects of Adding ω 3 Fatty Acids to Simvastatin on Lipids, Lipoprotein Size and Subspecies in Type 2 Diabetes Mellitus with Hypertriglyceridemia. <i>Korean Diabetes Journal</i> , 2009 , 33, 494		
30	High Density Lipoproteins, Dyslipidemia, and Heart Disease: Past, Present, and Future. 2010 , 181-199		
29	Seafood and Restructured Seafood. 2010 , 125-162		
28	Inflammatory Markers and Novel Risk Factors. 2011 , 107-123		

27	Diabetic Dyslipidemia. 2011 , 213-238			1
26	Low-Density Lipoprotein Cholesterol. 2011 , 215-229			
25	Cardiovascular risk and lipid control in secondary prevention. <i>Srce I Krvni Sudovi</i> , 2011 , 30, 210-219			
24	Fish Oils (Omega-3 Fatty Acids, Docosahexaenoic Acid, Eicosapentaenoic Acid, Dietary Fish, and Fish Oils). 2013 , 745-771			
23	Non-statin Therapies for CKD with Dyslipidemia. 2014 , 153-178			
22	Non-Statin Treatment of Dyslipidemia. 2015 , 201-231			
21	N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease. <i>Contemporary Endocrinology</i> , 2015 , 355-370		0.3	
20	Impact of Preventive Therapies on Clinical Management and Outcomes. 479-493			
19	Basic Facts about Antioxidants. 2016 , 27-38			
18	Basic Facts about Oxidative Stress, Inflammation, and the Immune System. 2016 , 39-48			
17	Research Progress of Application of Novel Li-pid-Regulating Drugs. <i>Pharmacy Information</i> , 2018 , 07, 74-78			
16	Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2020 , 20, 93-107		1.1	
15	THE EFFECTS OF LOW-DOSE ROSUVASTATIN ALONE OR IN COMBINATION WITH FENOFIBRATE OR OMEGA 3 FATTY ACIDS IN MIXED DYSLIPIDEMIA. 2020 , 1-3			
14	AGING OF THE SUBVENTRICULAR ZONE NEURAL STEM CELL NICHE. 2011 , 2, 149-163			13
13	Overview of omega-3 Fatty Acid therapies. <i>P and T</i> , 2013 , 38, 681-91		1.4	62
12	A Comparative Overview of Prescription Omega-3 Fatty Acid Products. <i>P and T</i> , 2015 , 40, 826-57		1.4	20
11	and Hypolipidemic Activity of Spinach Roots and Flowers. <i>Iranian Journal of Pharmaceutical Research</i> , 2017 , 16, 1509-1519		1.1	2
10	The effect of canola oil compared with sesame and sesame-canola oil on cardio-metabolic biomarkers in patients with type 2 diabetes: Design and research protocol of a randomized, triple-blind, three-way, crossover clinical trial. <i>ARYA Atherosclerosis</i> , 2019 , 15, 168-178		0.7	5

9	Nutrigenetics, omega-3 and plasma lipids/lipoproteins/apolipoproteins with evidence evaluation using the GRADE approach: a systematic review.. <i>BMJ Open</i> , 2022 , 12, e054417	3	2
8	Dietary supplementation for traumatic brain injury. 2022 , 485-494		
7	Evaluation of Functional and Bioactive Properties of Crude Gill Extract of <i>Tor putitora</i> using Different Assays. <i>International Journal of Food Science and Technology</i> ,	3.8	
6	N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial. 2022 , 21,		○
5	Suppression of Betacellulin expression is a key mechanism for omega-3 fatty acid mediated attenuation of nonalcoholic steatohepatitis.		○
4	The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials. 9,		○
3	The Potential Cardiometabolic Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies. 2023 ,		○
2	Dietary Supplementation with Linseed Oil Ethyl Esters Improves Sexual Behavior and Chosen Seminal Parameters in Porcine Species. 2023 , 13, 1347		○
1	Assessing the Highest Level of Evidence from Randomized Controlled Trials in Omega-3 Research. 2023 , 15, 1001		○